March 31, 2025 07:00 AM EDTUpdated 09:11 AM

Exclusive: Transcend notches Phase 2 win to treat PTSD, invigorating budding neuroplastogen class

Max Bayer

Pharma Reporter

Transcend Therapeutics’ PTSD treatment succeeded in a mid-stage study, propelling the scrappy company of less than 20 people toward a Phase 3 trial that could …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exclusive: Transcend notches Phase 2 win to treat PTSD, invigorating budding neuroplastogen class

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Firings sweep across FDA as former leaders lament the gutting of drug agency

RFK Jr. has long criticized drug ads. He just slashed the FDA office that regulates them

‘It’ll be a challenge’: BIO chief Crowley addresses seismic FDA overhaul

Sanofi continues its bet on R&D by poaching GSK’s head of development

Big ambitions at Merck and AstraZeneca — along with a few giant pitfalls — reshape top ranks of the R&D 15

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO

Ex­clu­sive: Tran­scend notch­es Phase 2 win to treat PTSD, in­vig­o­rat­ing bud­ding neu­ro­plas­to­gen class

Pharma Reporter

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

Exclusive: Transcend notches Phase 2 win to treat PTSD, invigorating budding neuroplastogen class